Mueller Health Foundation Inc.

Mueller Health Foundation Inc. is a small, hands-on family foundation founded in February 2015 by Peter Mueller, PhD (30+ years in pharma/biotech leadership, including Vertex Pharmaceuticals and Boehringer Ingelheim) and Ulrike Mueller (a German-trained medical technician with an infectious-disease research background). Judith Mueller serves as the foundation's Executive Director and only compensated officer ($97,425/year per its 990), running a deliberately small, collaborative team out of Garden City, NY, with assets administered through Bessemer Trust Company. The single most important fact for any prospective applicant: the foundation does not accept unsolicited proposals. It identifies grantees by 'talking to and meeting individuals and organizations' already active in its three priority areas — clinical research, data/technology initiatives, and education and public health — rather than through open RFPs. This makes it a relationship-driven, invitation-style funder rather than a competitive-application one. Once a relationship exists, the foundation runs a structured two-stage process: a two-page concept note (project overview, requested USD amount, and key performance indicators) reviewed first by staff and then the Executive Team, followed — if approved — by a full proposal with detailed budget and a financial/legal/risk due-diligence review, alongside collaborative design of an impact measurement framework. The foundation estimates roughly 12 weeks from concept-note approval to final funding decision. IRS filings and the foundation's own site both point to a 'few large, deep partnerships' model rather than broad-based grantmaking: Cornell University (specifically the Russell Lab) has received three grants totaling $1,589,370 (average $529,790 each) per available 990 data, while the foundation's own website names Boston Children's Hospital's Precision Vaccines Program as its top recipient since inception, alongside a partner referred to only as 'Reach.' First-time contacts should not lead with a full proposal — the realistic opening move is visibility within TB and drug-resistant-infection research networks, a warm introduction from an existing partner (Cornell, Boston Children's), or registering for the foundation's TBConnect beta platform via info@muellerhealthfoundation.org.

Grants paid have climbed steadily since the foundation restarted active grantmaking in 2020: $0 in FY2019, $475,012 in FY2020, $497,480 in FY2021, $545,945 in FY2022, and $584,739 in FY2023 (total giving, which includes grants plus program costs, was $757,417 in FY2023). Total assets have hovered in a narrow band, from $4.79M (2019) to a peak of $6.32M (2021) before settling at $5.53M in FY2023, reflecting a foundation living mostly off investment returns and periodic family contributions ($501,362 received in 2021; $106,077 in 2023) rather than aggressive endowment growth. Per the foundation's own 'Grants' page, cumulative giving since inception in 2015 totals $4,016,000 through 2024, split heavily toward Clinical Research ($3.55M, the dominant category), with much smaller allocations to Data Initiatives ($316,000) and Education & Health ($150,000) — a roughly 88%/8%/4% split. Available IRS/990-derived grantee data (a partial sample, not the full grants list) shows Cornell University receiving 3 grants for $1,589,370 total, averaging $529,790 per grant, all in New York and all coded 'general exempt purpose' — consistent with large, multi-year research-support gifts rather than small program grants. There is a notable gap between the foundation's self-reported top recipient (Boston Children's Hospital, called out on its own site as the primary grantee since 2015) and what shows up in the sampled 990 grantee data (Cornell only) — a reminder that the public grantee record here is incomplete and that Boston Children's, the Precision Vaccines Program, and 'Reach' likely account for a meaningful share of the $3.55M clinical-research total not reflected in this dataset. Net takeaway for applicants: this is a low-volume, high-concentration funder — a handful of institutional partners, each receiving grants in the low-to-mid six figures, sustained over multiple years, rather than a funder making many small one-off awards.

Mueller Health Foundation's $5.56M in assets sits squarely in a cluster of similarly sized health-focused private foundations, though most peers disclose far less publicly about giving levels or process.

All five peers cluster within about $500,000 of Mueller's asset base, suggesting comparable capacity for annual grantmaking (typically 8-12% of assets for active foundations, which for this cohort implies roughly $430K-$700K/year — consistent with Mueller's own $585K-$757K). What differentiates Mueller from this peer set is transparency and specialization: it publishes a defined three-pillar strategy (clinical research, data/technology, education), a stated two-stage process, and a named disease focus (TB and drug-resistant infection), while the available data on the peer foundations does not surface comparable public detail on focus or process — meaning grant seekers would need direct outreach or 990 review to assess fit with those funders.

The foundation's most substantive recent initiative is TBMeld®, an AI/machine-learning platform built with technology partner InveniAI to accelerate identification of therapies and vaccine candidates for tuberculosis — positioned on the foundation's 'Our Work' page as the leading edge of its data-and-technology pillar. It also continues to beta-test TBConnect, a blockchain-based application/data platform, with new organizations invited to register by emailing the TBConnect systems administrator directly. On the public-facing side, the foundation marked World TB Day on March 24, 2026 under the global theme 'Yes! We Can End TB,' consistent with its long-standing TB emphasis. Communications activity is steady but narrow: the foundation has published a monthly newsletter, 'The Monthly Dose,' every month from at least May 2025 through April 2026 without a gap, but each issue shows only about 89 recorded views — indicating the newsletter serves a small, likely partner/insider list rather than functioning as a public-outreach or grantee-recruitment channel. No leadership changes, new board appointments, or major new grant announcements surfaced in available web sources for 2025-2026; Peter Mueller (President), Ulrike Mueller (Treasurer/Secretary), and Judith Mueller (Executive Director) appear to remain the sole officers, matching the governance structure reported in the most recent 990 filings. Overall, the pattern is one of quiet continuity — sustained TB-focused grantmaking and a slow build-out of technology tools — rather than any recent pivot, crisis, or expansion.

Do not submit a cold proposal or LOI — the foundation states directly that it does not accept unsolicited applications, and its entire model is built around identifying partners through direct relationships in clinical research, data/technology, and education/public health for lethal infectious diseases (with a clear emphasis on tuberculosis and antimicrobial resistance). The realistic path in is visibility: publish or present research on TB, drug-resistant infections, or related diagnostics/vaccines in venues the foundation's small team is likely to see, or secure an introduction through an existing partner such as Cornell's Russell Lab or Boston Children's Hospital's Precision Vaccines Program. A second concrete option is registering for the TBConnect beta platform by emailing info@muellerhealthfoundation.org with your name, organization, title, and preferred contact email — this is the one self-service entry point the foundation has publicly documented. If a relationship does develop, be ready to move fast and lean on data: the first ask is a tight two-page concept note covering the project overview, a specific USD funding amount, and measurable KPIs — vague asks or missing metrics will stall at the Executive Team review stage. Emphasize the four attributes the foundation says it screens for explicitly: bold (genuinely innovative, not incremental), measurable (data-driven with clear KPIs), open (collaborative, willing to share data/results), and lasting (built for scalable, sustained impact rather than a one-time intervention). Expect real due diligence if you clear the concept-note stage — financial, legal, and risk review plus co-design of an impact measurement framework — and budget roughly 12 weeks from concept-note approval to a funding decision, so this is not a funder to approach against a tight, near-term deadline. Given that confirmed grants (per available 990 data) average around $530,000 and run for multiple years to the same institutions, position any ask as part of a sustained research or program relationship rather than a small, discrete project — this foundation funds depth with a few partners, not breadth across many.